Identifying new treatments for multiple sclerosis by targeting a specific protein.
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis
This study is looking for new ways to help people with multiple sclerosis by finding special chemicals that can change how a protein called Hectd3 works, which is important for the immune system and the disease's progression, with the hope of creating safer and more effective treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11056112 on NIH RePORTER |
What this research studies
This research focuses on finding new chemical probes that can target Hectd3, a protein involved in the immune response related to multiple sclerosis. The approach involves high throughput screening assays to identify compounds that can modulate the activity of Hectd3, which has been shown to play a significant role in the disease's progression. By understanding how Hectd3 affects immune cells, the research aims to develop novel therapies that could reduce the severity of multiple sclerosis and its symptoms. Patients may benefit from potential new treatment options that are safer and more effective than current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis who are seeking new treatment options.
Not a fit: Patients with other autoimmune diseases not related to multiple sclerosis may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, safer treatments for multiple sclerosis that reduce disease symptoms and improve patient quality of life.
How similar studies have performed: Previous research has shown promising results in targeting similar proteins for autoimmune diseases, indicating potential for success in this approach.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Li, Hongmin — University of Arizona
- Study coordinator: Li, Hongmin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.